Company profile
Karyopharm Therapeutics Inc.
Pipeline4 assets
- SelinexorKPT-330 / XPOVIO / XPO1 (Exportin 1) / Small Molecule / OncologyMultiple MyelomaMarketedActiveUSGlobalEndometrial CancerPhase 3ActiveUSGlobalMyelofibrosisPhase 3ActiveUSGlobal
- EltanexorKPT-8602 / XPO1 (Exportin 1) / Small Molecule / OncologyMyelodysplastic NeoplasmsPhase 2PausedUSColorectal CancerPhase 2PausedUSProstate CancerPhase 2PausedUS
- KPT-9274KPT-9274 / PAK4 / NAMPT / Small Molecule / OncologySolid Tumors & LymphomaPhase 1PausedUS
- VerdinexorKPT-335 / XPO1 (Exportin 1) / Small Molecule / Veterinary Oncology / Infectious DiseasesCanine LymphomaMarketedActiveUS
Latest news15 items
All newsKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Results Call • Phase 3Results call Mon, Jun 8, 2026, 12:00 PM ET
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Presentation / Abstract • Phase 3Late-Breaking Oral Presentation Sun, Jun 14, 2026, 9:15 AM CEST
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Trial Results • Phase 3ASCO oral presentation Tue, Jun 2, 2026, 9:45 AM CT
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Results Call • Phase 3Results call Tue, Jun 2, 2026, 2:00 PM ET
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Enrollment • Phase 3Enrollment completion Thu, May 14, 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
Presentation / Abstract • Phase 3